"I am proud to be part of the scientific team at Genentech that values scientific excellence above all to fuel therapeutic programs for patients in need."
When I came to Genentech in 2009 as a postdoc, I had the opportunity to witness groundbreaking science performed by smart and creative people using cutting-edge technology and excellent resources. Thus, it was not a hard decision to join the Neuroscience department in 2010 to pursue treatments for neurodegenerative disorders. To this end, I am leading a research program aimed at identifying novel therapeutic targets in mitochondrial and lysosomal biology.
Postdocs have a critical role at Genentech in driving basic science projects, which often times lay the foundation for future therapeutic discoveries. Postdoc projects in my lab take cues from genetics of human disease to reveal novel biology and cellular mechanisms of proteostasis.
Having been a postdoc myself at Genentech, I know how engaging and rewarding the postdoc program is. It is a truly unique experience in a research environment that fosters scientific excellence, creativity, collaboration and fun.
Neuron 69 1 pg.22-32 2011 [1097-4199]
Bingol B, Sheng M.
Cell 140 4 pg.567-578 2010 [0092-8674]
Bingol B, Wang CF, Arnott D, Cheng D, Peng J, Sheng M.
My group is focused on understanding the molecular mechanisms of cellular proteostasis. We believe a better understanding of the organelle and protein clearance in cells will yield novel therapeutic targets to boost the quality of the cellular proteome. One current project examines how neurons eliminate damaged mitochondria and how this mitochondrial quality control is disturbed in disease. A second project focuses on defects in lysosomal degradation to understand molecular mechanisms of toxic protein build-up in neurodegenerative disease.